140 related articles for article (PubMed ID: 28546731)
1. Discordance in Immunohistochemical Status of Breast Cancer Post Neoadjuvant Chemotherapy.
Agrawal SK; Chatterjee S; Arun I; Ahmed R
Indian J Surg Oncol; 2017 Jun; 8(2):245-246. PubMed ID: 28546731
[No Abstract] [Full Text] [Related]
2. Discordance of Estrogen & Progesterone Receptors After Neoadjuvant Chemotherapy in Breast Cancer- an Indian Study.
Anand AS; Velayudhan ST
Indian J Surg Oncol; 2016 Sep; 7(3):316-9. PubMed ID: 27651692
[TBL] [Abstract][Full Text] [Related]
3. Biomarker discordance pre and post neoadjuvant chemotherapy in breast cancer.
Dawood S; Gonzalez-Angulo AM
Cancer Biomark; 2012-2013; 12(6):241-50. PubMed ID: 23735944
[TBL] [Abstract][Full Text] [Related]
4. Factors influencing HER2 discordance in nonmetastatic breast cancer and the role of neoadjuvant therapy.
Ebinç S; Oruç Z; Sezgin Y; Karhan O; Bilen E; Yerlikaya H; Kalkan Z; Urakçı Z; Küçüköner M; Kaplan MA; Işikdoğan A
Future Oncol; 2022 Sep; 18(30):3399-3408. PubMed ID: 36069377
[TBL] [Abstract][Full Text] [Related]
5. Discordance of estrogen and progesterone receptors after neoadjuvant chemotherapy in locally advanced breast cancer.
Gupta S; Anto A; Singhal J; Agarwal P
J Cancer Res Ther; 2023 Apr; 19(Supplement):S0. PubMed ID: 37147956
[TBL] [Abstract][Full Text] [Related]
6. Biomarker Discordances and Alterations Observed in Breast Cancer Treated with Neoadjuvant Chemotherapy: Causes, Frequencies, and Clinical Significances.
Yilmaz C; Cavdar DK
Curr Oncol; 2022 Dec; 29(12):9695-9710. PubMed ID: 36547175
[TBL] [Abstract][Full Text] [Related]
7. Factors associated with radiologic-pathologic discordance in magnetic resonance imaging after neoadjuvant chemotherapy for breast cancer.
Kwon MR; Chu J; Kook SH; Kim EY
Clin Imaging; 2022 Sep; 89():1-9. PubMed ID: 35654000
[TBL] [Abstract][Full Text] [Related]
8. Effect of HER2-low expression on neoadjuvant efficacy in operable breast cancer.
Yi X; Hu S; Ma M; Huang D; Zhang Y
Clin Transl Oncol; 2024 Apr; 26(4):880-890. PubMed ID: 37702827
[TBL] [Abstract][Full Text] [Related]
9. Impact on survival of estrogen receptor, progesterone receptor and Ki-67 expression discordance pre- and post-neoadjuvant chemotherapy in breast cancer.
Ding Y; Ding K; Qian H; Yu X; Zou D; Yang H; Mo W; He X; Zhang F; Qin C; Zheng Y; Ding X
PLoS One; 2020; 15(4):e0231895. PubMed ID: 32298374
[TBL] [Abstract][Full Text] [Related]
10. Clinical importance of discordance of hormone receptors and Her2/neu status after neoadjuvant chemotherapy in breast cancer.
Basak Oven Ustaalioglu B; Aker Vardar F; Bilici A; Gurleyik G; Erkol B; Kefeli U; Aliustaoglu M
J BUON; 2014; 19(4):879-86. PubMed ID: 25536590
[TBL] [Abstract][Full Text] [Related]
11. The effect of neoadjuvant chemotherapy on hormone receptor status, HER2/neu and prolactin in breast cancer.
Pedrini JL; Francalacci Savaris R; Casales Schorr M; Cambruzi E; Grudzinski M; Zettler CG
Tumori; 2011; 97(6):704-10. PubMed ID: 22322835
[TBL] [Abstract][Full Text] [Related]
12. Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21,755 patients from the Japanese breast cancer registry.
Niikura N; Tomotaki A; Miyata H; Iwamoto T; Kawai M; Anan K; Hayashi N; Aogi K; Ishida T; Masuoka H; Iijima K; Masuda S; Tsugawa K; Kinoshita T; Nakamura S; Tokuda Y
Ann Oncol; 2016 Mar; 27(3):480-7. PubMed ID: 26704052
[TBL] [Abstract][Full Text] [Related]
13. RB-pathway disruption is associated with improved response to neoadjuvant chemotherapy in breast cancer.
Witkiewicz AK; Ertel A; McFalls J; Valsecchi ME; Schwartz G; Knudsen ES
Clin Cancer Res; 2012 Sep; 18(18):5110-22. PubMed ID: 22811582
[TBL] [Abstract][Full Text] [Related]
14. [Effect of neoadjuvant chemotherapy on histologic grade and expression of biological markers in breast cancer].
Yin HF; Wang YH; Qin XQ; Zhang H; Li T; Ye JM; Liu YH
Zhonghua Zhong Liu Za Zhi; 2009 Nov; 31(11):858-62. PubMed ID: 20137353
[TBL] [Abstract][Full Text] [Related]
15. Receptor discordance rate and its effects on survival in primary and recurrent breast cancer patients.
Ilgun S; Sarsenov D; Erdogan Z; Ordu C; Celebi F; Nur Pilanci K; Ozturk A; Selamoglu D; Alco G; Aktepe F; Eralp Y; Tuzlali S; Ozmen V
J BUON; 2016; 21(6):1425-1432. PubMed ID: 28039703
[TBL] [Abstract][Full Text] [Related]
16. High expression of class III β-tubulin predicts good response to neoadjuvant taxane and doxorubicin/cyclophosphamide-based chemotherapy in estrogen receptor-negative breast cancer.
Wang Y; Sparano JA; Fineberg S; Stead L; Sunkara J; Horwitz SB; McDaid HM
Clin Breast Cancer; 2013 Apr; 13(2):103-8. PubMed ID: 23218766
[TBL] [Abstract][Full Text] [Related]
17. Incidence and prognostic impact of HER2-positivity loss after dual HER2-directed neoadjuvant therapy for HER2+ breast cancer.
LeVee A; Spector K; Larkin B; Dezem F; Plummer J; Dadmanesh F; Patil S; McArthur HL
Cancer Med; 2023 May; 12(9):10647-10659. PubMed ID: 36971049
[TBL] [Abstract][Full Text] [Related]
18. Ultrasound is at least as good as magnetic resonance imaging in predicting tumour size post-neoadjuvant chemotherapy in breast cancer.
Vriens BE; de Vries B; Lobbes MB; van Gastel SM; van den Berkmortel FW; Smilde TJ; van Warmerdam LJ; de Boer M; van Spronsen DJ; Smidt ML; Peer PG; Aarts MJ; Tjan-Heijnen VC;
Eur J Cancer; 2016 Jan; 52():67-76. PubMed ID: 26650831
[TBL] [Abstract][Full Text] [Related]
19. Correlation between the expression of S100A4 and the efficacy of TAC neoadjuvant chemotherapy in breast cancer.
Li WL; Zhang Y; Liu BG; DU Q; Zhou CX; Tian XS
Exp Ther Med; 2015 Nov; 10(5):1983-1989. PubMed ID: 26640584
[TBL] [Abstract][Full Text] [Related]
20. [Analyses of the Expression of FBI-1 in Breast Cancer Pre- and Pro-neoadjuvant Chemotherapy].
Mao AY; Chen MJ; Jiang W; Wang L; Qin QH; Tan QX; Yang WP; Wei CY
Zhonghua Yi Xue Za Zhi; 2018 Dec; 98(46):3751-3755. PubMed ID: 30541216
[No Abstract] [Full Text] [Related]
[Next] [New Search]
